MedTrace Logo

iCAT for Recurrent/Refractory/HR Solid Tumors

NCT01853345 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2015-02-10

No results posted yet for this study

Summary

In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is, the experts will determine if there is a targeted drug available that could counteract this alteration. If there is an alteration identified and a targeted drug available the panel of experts will make an individualized treatment recommendation. The results of the tumor profiling and the individualized treatment recommendation can be shared with the primary oncologist.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Katherine Janeway, MD · Dana-Farber Cancer Institute

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01853345 on ClinicalTrials.gov